Firefly Neuroscience, Inc. (AIFF) Key Metrics
AIFF valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $16.0M
- Enterprise value
- $16.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 8.9 10-yr median 52.4
- Price / book
- 1.2 10-yr median 212.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −4.04
AIFF key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAIFF valuation Price multiples at each fiscal year-end price.
Price / sales−93.5%
10.4
2025 · hover or tap a bar for each year
20202025
Price / book
1.6
2025 · hover or tap a bar for each year
20202025
Free cash flow yield−32.2 pts
−70.1%
2025 · hover or tap a bar for each year
20202025
AIFF returns How much profit the business earns on the capital it uses.
Return on equity
−547.6%
2025 · hover or tap a bar for each year
20202025
Return on invested capital
−400.0%
2025 · hover or tap a bar for each year
20202025
Return on assets+25.1 pts
−263.7%
2025 · hover or tap a bar for each year
20202025
Free cash flow margin
−728.7%
2025 · hover or tap a bar for each year
20202025
Asset turnover+407.9%
0.15
2025 · hover or tap a bar for each year
20202025
AIFF per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+412.9%
$0.08
2025 · hover or tap a bar for each year
20202025
Earnings per share
−$1.47
2025 · hover or tap a bar for each year
20202025
Free cash flow per share
−$0.62
2025 · hover or tap a bar for each year
20202025
Book value per share
$0.57
2025 · hover or tap a bar for each year
20202025
Shares outstanding+106.2%
13.5M
2025 · hover or tap a bar for each year
20202025
AIFF financial health Debt, liquidity and how easily interest is covered.
Net debt−$1.6M
−$2.7M
2025 · hover or tap a bar for each year
20202025
Current ratio+170.5%
1.43
2025 · hover or tap a bar for each year
20202025
Interest coverage
-54.1
2025 · hover or tap a bar for each year
20202025
AIFF efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−296 days
50 days
2025 · hover or tap a bar for each year
20202025
Days payables outstanding−5,501 days
1,161 days
2025 · hover or tap a bar for each year
20202025
Cash conversion cycle+5,245 days
-1,071 days
2025 · hover or tap a bar for each year
20202025
Capex / revenue−373.1 pts
11.2%
2025 · hover or tap a bar for each year
20202025
AIFF valuation history
Fiscal year-endToday6-year median
AIFF returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AIFF debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AIFF price vs earnings per share
Share price at year-endEPS (right axis)
AIFF key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $11.9M | $17.3M | $39.9M | $113.3M | $1.17B | $342.4M |
| Enterprise value | $9.1M | $16.2M | $37.8M | $113.3M | $1.17B | $341.0M |
| P/E ratio | — | — | — | — | — | 828.2 |
| Price / sales | 10.4 | 160.6 | 80.1 | — | — | 24.6 |
| Price / book | 1.6 | — | 366.1 | — | — | 212.2 |
| Price / free cash flow | — | — | — | — | — | 954.4 |
| Price / operating cash flow | — | — | — | — | — | 808.8 |
| EV / sales | 8.0 | 150.3 | 75.8 | — | — | 24.5 |
| EV / EBITDA | — | — | — | — | — | 801.5 |
| EV / free cash flow | — | — | — | — | — | 950.6 |
| Earnings yield | −167.4% | −60.3% | −6.5% | −3.3% | −0.4% | 0.1% |
| Free cash flow yield | −70.1% | −37.9% | −6.4% | −2.6% | −0.3% | 0.1% |
| Share price at fiscal year-end | $0.88 | $2.65 | $5.07 | $14.40 | $148.50 | $43.50 |
| Per share | ||||||
| Revenue per share | $0.08 | $0.02 | $0.06 | $0.00 | $0.00 | $1.77 |
| Earnings per share | −$1.47 | −$1.60 | −$0.33 | −$0.48 | −$0.56 | $0.05 |
| Operating cash flow per share | −$0.61 | −$0.94 | −$0.28 | −$0.37 | −$0.49 | $0.05 |
| Free cash flow per share | −$0.62 | −$1.00 | −$0.33 | −$0.37 | −$0.49 | $0.05 |
| Cash per share | $0.20 | $0.28 | $0.27 | $0.01 | $0.08 | $0.24 |
| Book value per share | $0.57 | −$0.06 | $0.01 | −$0.27 | −$0.38 | $0.20 |
| Tangible book value per share | $0.12 | −$0.08 | −$0.04 | −$0.27 | −$0.38 | $0.20 |
| Capex per share | $0.01 | $0.06 | $0.05 | $0.00 | $0.00 | $0.01 |
| Debt per share | — | $0.11 | — | — | $0.23 | $0.06 |
| Shares outstanding | 13.5M | 6.5M | 7.9M | 7.9M | 7.9M | 7.9M |
| Change in shares outstanding | +106.2% | −16.8% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −547.6% | — | — | — | — | 25.6% |
| Return on invested capital (ROIC) | −400.0% | — | — | — | — | 129.7% |
| Return on assets (ROA) | −263.7% | −288.9% | −187.5% | −696.5% | −185.4% | 11.0% |
| Return on tangible assets | −447.7% | −236.6% | −115.4% | — | −460.2% | 11.0% |
| Free cash flow margin | −728.7% | — | −513.7% | — | — | 2.6% |
| Income quality (OCF / net income) | — | — | — | — | — | 1.02 |
| Financial health | ||||||
| Total debt | — | $694,000 | — | — | $1.8M | $495,595 |
| Cash & short-term investments | $2.7M | $1.8M | $2.1M | $58,000 | $653,000 | $1.9M |
| Net debt | −$2.7M | −$1.1M | −$2.1M | −$58,000 | $1.1M | −$1.4M |
| Debt / equity | — | — | — | — | — | 0.31 |
| Debt / assets | — | 0.15 | — | — | 1.88 | 0.13 |
| Net debt / EBITDA | — | — | — | — | — | −3.20 |
| Current ratio | 1.43 | 0.53 | 0.89 | 0.04 | 0.18 | 1.86 |
| Quick ratio | 1.39 | 0.53 | 0.89 | 0.04 | 0.18 | 1.86 |
| Interest coverage | -54.1 | -133.0 | -171.0 | -5.8 | -34.5 | — |
| Working capital | $1.2M | −$2.3M | −$277,000 | −$2.2M | −$3.3M | $1.6M |
| Invested capital | $4.9M | −$1.5M | −$2.0M | −$2.2M | −$1.9M | $250,818 |
| Tangible asset value | $1.6M | −$555,000 | −$277,000 | −$2.1M | −$3.0M | $1.6M |
| Net current asset value | $1.2M | −$2.3M | −$277,000 | −$2.2M | −$3.3M | $1.2M |
| Graham number | — | — | — | — | — | $0.49 |
| Graham net-net per share | $0.01 | −$0.47 | −$0.04 | −$0.28 | −$0.42 | $0.10 |
| Capital allocation | ||||||
| Capex / revenue | 11.2% | 384.3% | 77.5% | — | 0.0% | 0.5% |
| Capex / operating cash flow | — | — | — | — | — | 15.2% |
| Capex / depreciation | 0.74 | 6.19 | — | 0.00 | 0.00 | 5.35 |
| Stock-based compensation / revenue | 68.4% | 2,519.4% | 59.2% | — | 1,900.0% | — |
| R&D / revenue | 129.8% | 1,809.3% | 148.8% | — | 9,143.8% | — |
| SG&A / revenue | 680.2% | 6,790.7% | 569.3% | — | 5,253.1% | — |
| Efficiency | ||||||
| Days sales outstanding | 50.3 | 346.4 | 37.7 | — | 8,459.1 | 37.9 |
| Days of inventory on hand | 39.7 | — | — | — | — | — |
| Days payables outstanding | 1,161.5 | 6,662.6 | — | — | — | 3.2 |
| Cash conversion cycle (days) | -1,071.5 | -6,316.2 | — | — | — | 34.6 |
| Receivables turnover | 7.25 | 1.05 | 9.67 | 0.00 | 0.04 | 9.64 |
| Payables turnover | 0.31 | 0.05 | 0.00 | 0.00 | 0.00 | 112.82 |
| Inventory turnover | 9.20 | — | — | — | — | — |
| Asset turnover | 0.15 | 0.03 | 0.36 | 0.00 | 0.01 | 3.68 |
| Average receivables | $157,500 | $102,500 | $51,500 | $30,000 | $741,616 | $1.4M |
| Average payables | $1.6M | $1.2M | $525,000 | $460,000 | $301,823 | $103,646 |
| Average inventory | $54,000 | $0 | — | — | — | — |
| Intangibles / total assets | 57.6% | 3.9% | 14.6% | 0.0% | 0.1% | 0.0% |
Computed from AIFF's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AIFF valuation and financial ratios
Firefly Neuroscience earned a return on equity of −547.6% and a return on invested capital of −400.0% in fiscal 2025. The share count rose 71.5% from 7.9M to 13.5M over 5 years.
See the AIFF income statement, the AIFF chart for price history, or the AIFF stock overview for the latest quote and news.
AIFF key metrics FAQ
What is Firefly Neuroscience's return on equity?
Firefly Neuroscience's return on equity (ROE) was −547.6% in fiscal 2025: net income of -$19.9 million on average shareholders' equity of $3.6 million.
What is Firefly Neuroscience's ROIC?
Firefly Neuroscience's return on invested capital was −400.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Firefly Neuroscience's free cash flow yield?
Firefly Neuroscience generated -$8.3 million of free cash flow in fiscal 2025, a free cash flow yield of −70.1% on its market value at year-end ($11.9 million).
What is Firefly Neuroscience's current ratio?
Firefly Neuroscience's current ratio was 1.43 at the end of fiscal 2025: current assets were 1.43 times current liabilities.